Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 50

1.

Unique Neoantigens Arise from Somatic Mutations in Patients with Gastrointestinal Cancers.

Parkhurst MR, Robbins PF, Tran E, Prickett TD, Gartner JJ, Jia L, Ivey G, Li YF, El-Gamil M, Lalani A, Crystal JS, Sachs A, Groh E, Ray S, Ngo LT, Kivitz S, Pasetto A, Yossef R, Lowery FJ, Goff SL, Lo W, Cafri G, Deniger DC, Malekzadeh P, Ahmadzadeh M, Wunderlich JR, Somerville RPT, Rosenberg SA.

Cancer Discov. 2019 Aug;9(8):1022-1035. doi: 10.1158/2159-8290.CD-18-1494. Epub 2019 Jun 4.

PMID:
31164343
2.

Metformin hydrochloride and wound healing: from nanoformulation to pharmacological evaluation.

El-Ridy MS, Yehia SA, Elsayed I, Younis MM, Abdel-Rahman RF, El-Gamil MA.

J Liposome Res. 2019 Dec;29(4):343-356. doi: 10.1080/08982104.2018.1556291. Epub 2019 Jan 31.

PMID:
30526146
3.

Durable Complete Response from Metastatic Melanoma after Transfer of Autologous T Cells Recognizing 10 Mutated Tumor Antigens.

Prickett TD, Crystal JS, Cohen CJ, Pasetto A, Parkhurst MR, Gartner JJ, Yao X, Wang R, Gros A, Li YF, El-Gamil M, Trebska-McGowan K, Rosenberg SA, Robbins PF.

Cancer Immunol Res. 2016 Aug;4(8):669-78. doi: 10.1158/2326-6066.CIR-15-0215. Epub 2016 Jun 16.

4.

Isolation and Characterization of an HLA-DPB1*04: 01-restricted MAGE-A3 T-Cell Receptor for Cancer Immunotherapy.

Yao X, Lu YC, Parker LL, Li YF, El-Gamil M, Black MA, Xu H, Feldman SA, van der Bruggen P, Rosenberg SA, Robbins PF.

J Immunother. 2016 Jun;39(5):191-201. doi: 10.1097/CJI.0000000000000123.

5.

Isolation of neoantigen-specific T cells from tumor and peripheral lymphocytes.

Cohen CJ, Gartner JJ, Horovitz-Fried M, Shamalov K, Trebska-McGowan K, Bliskovsky VV, Parkhurst MR, Ankri C, Prickett TD, Crystal JS, Li YF, El-Gamil M, Rosenberg SA, Robbins PF.

J Clin Invest. 2015 Oct 1;125(10):3981-91. doi: 10.1172/JCI82416. Epub 2015 Sep 21.

6.

A pilot trial using lymphocytes genetically engineered with an NY-ESO-1-reactive T-cell receptor: long-term follow-up and correlates with response.

Robbins PF, Kassim SH, Tran TL, Crystal JS, Morgan RA, Feldman SA, Yang JC, Dudley ME, Wunderlich JR, Sherry RM, Kammula US, Hughes MS, Restifo NP, Raffeld M, Lee CC, Li YF, El-Gamil M, Rosenberg SA.

Clin Cancer Res. 2015 Mar 1;21(5):1019-27. doi: 10.1158/1078-0432.CCR-14-2708. Epub 2014 Dec 23.

7.

Efficient identification of mutated cancer antigens recognized by T cells associated with durable tumor regressions.

Lu YC, Yao X, Crystal JS, Li YF, El-Gamil M, Gross C, Davis L, Dudley ME, Yang JC, Samuels Y, Rosenberg SA, Robbins PF.

Clin Cancer Res. 2014 Jul 1;20(13):3401-10. doi: 10.1158/1078-0432.CCR-14-0433.

8.

Structural, spectral, pH-metric and biological studies on mercury (II), cadmium (II) and binuclear zinc (II) complexes of NS donor thiosemicarbazide ligand.

El-Gammal OA, Abu El-Reash GM, El-Gamil MM.

Spectrochim Acta A Mol Biomol Spectrosc. 2014 Apr 5;123:59-70. doi: 10.1016/j.saa.2013.12.034. Epub 2013 Dec 17.

PMID:
24389001
9.

Mutated PPP1R3B is recognized by T cells used to treat a melanoma patient who experienced a durable complete tumor regression.

Lu YC, Yao X, Li YF, El-Gamil M, Dudley ME, Yang JC, Almeida JR, Douek DC, Samuels Y, Rosenberg SA, Robbins PF.

J Immunol. 2013 Jun 15;190(12):6034-42. doi: 10.4049/jimmunol.1202830. Epub 2013 May 20.

10.

Mining exomic sequencing data to identify mutated antigens recognized by adoptively transferred tumor-reactive T cells.

Robbins PF, Lu YC, El-Gamil M, Li YF, Gross C, Gartner J, Lin JC, Teer JK, Cliften P, Tycksen E, Samuels Y, Rosenberg SA.

Nat Med. 2013 Jun;19(6):747-52. doi: 10.1038/nm.3161. Epub 2013 May 5.

11.

Structural, spectral, DFT, pH-metric and biological studies on Cr(III), Mn(II) and Fe(III) complexes of dithione heterocyclic thiosemicarbazide ligand.

Abu El-Reash GM, El-Gammal OA, El-Gamil MM.

Spectrochim Acta A Mol Biomol Spectrosc. 2013 Mar;104:383-93. doi: 10.1016/j.saa.2012.11.070. Epub 2012 Dec 5.

PMID:
23274266
12.

Characterization of T-cell receptors directed against HLA-A*01-restricted and C*07-restricted epitopes of MAGE-A3 and MAGE-A12.

Zhu S, Van den Eynde BJ, Coulie PG, Li YF, El-Gamil M, Rosenberg SA, Robbins PF.

J Immunother. 2012 Nov-Dec;35(9):680-8. doi: 10.1097/CJI.0b013e31827338ea.

13.

Binuclear copper(II), cobalt(II) and nickel(II) complexes of N1-ethyl-N2-(pyridin-2-yl) hydrazine-1,2-bis(carbothioamide): structural, spectral, pH-metric and biological studies.

El-Gammal OA, Abu El-Reash GM, El-Gamil MM.

Spectrochim Acta A Mol Biomol Spectrosc. 2012 Oct;96:444-55. doi: 10.1016/j.saa.2012.05.046. Epub 2012 May 24.

PMID:
22728235
14.

An antigenic peptide produced by reverse splicing and double asparagine deamidation.

Dalet A, Robbins PF, Stroobant V, Vigneron N, Li YF, El-Gamil M, Hanada K, Yang JC, Rosenberg SA, Van den Eynde BJ.

Proc Natl Acad Sci U S A. 2011 Jul 19;108(29):E323-31. doi: 10.1073/pnas.1101892108. Epub 2011 Jun 13.

15.

Irradiation enhances human T-cell function by upregulating CD70 expression on antigen-presenting cells in vitro.

Huang J, Wang QJ, Yang S, Li YF, El-Gamil M, Rosenberg SA, Robbins PF.

J Immunother. 2011 May;34(4):327-35. doi: 10.1097/CJI.0b013e318216983d.

16.

Tumor regression in patients with metastatic synovial cell sarcoma and melanoma using genetically engineered lymphocytes reactive with NY-ESO-1.

Robbins PF, Morgan RA, Feldman SA, Yang JC, Sherry RM, Dudley ME, Wunderlich JR, Nahvi AV, Helman LJ, Mackall CL, Kammula US, Hughes MS, Restifo NP, Raffeld M, Lee CC, Levy CL, Li YF, El-Gamil M, Schwarz SL, Laurencot C, Rosenberg SA.

J Clin Oncol. 2011 Mar 1;29(7):917-24. doi: 10.1200/JCO.2010.32.2537. Epub 2011 Jan 31.

17.

No correlation between clinical response to CTLA-4 blockade and presence of NY-ESO-1 antibody in patients with metastatic melanoma.

Goff SL, Robbins PF, El-Gamil M, Rosenberg SA.

J Immunother. 2009 Oct;32(8):884-5. doi: 10.1097/CJI.0b013e3181affbf0. No abstract available.

18.

Recognition of NY-ESO-1+ tumor cells by engineered lymphocytes is enhanced by improved vector design and epigenetic modulation of tumor antigen expression.

Wargo JA, Robbins PF, Li Y, Zhao Y, El-Gamil M, Caragacianu D, Zheng Z, Hong JA, Downey S, Schrump DS, Rosenberg SA, Morgan RA.

Cancer Immunol Immunother. 2009 Mar;58(3):383-94. doi: 10.1007/s00262-008-0562-x. Epub 2008 Aug 2.

19.

Single and dual amino acid substitutions in TCR CDRs can enhance antigen-specific T cell functions.

Robbins PF, Li YF, El-Gamil M, Zhao Y, Wargo JA, Zheng Z, Xu H, Morgan RA, Feldman SA, Johnson LA, Bennett AD, Dunn SM, Mahon TM, Jakobsen BK, Rosenberg SA.

J Immunol. 2008 May 1;180(9):6116-31.

20.

Enhanced antitumor activity of T cells engineered to express T-cell receptors with a second disulfide bond.

Cohen CJ, Li YF, El-Gamil M, Robbins PF, Rosenberg SA, Morgan RA.

Cancer Res. 2007 Apr 15;67(8):3898-903.

21.

Modulation by IL-2 of CD70 and CD27 expression on CD8+ T cells: importance for the therapeutic effectiveness of cell transfer immunotherapy.

Huang J, Kerstann KW, Ahmadzadeh M, Li YF, El-Gamil M, Rosenberg SA, Robbins PF.

J Immunol. 2006 Jun 15;176(12):7726-35.

22.

Clonal persistence and evolution during a decade of recurrent melanoma.

Wang E, Voiculescu S, Le Poole IC, El-Gamil M, Li X, Sabatino M, Robbins PF, Nickoloff BJ, Marincola FM.

J Invest Dermatol. 2006 Jun;126(6):1372-7.

23.

Survival, persistence, and progressive differentiation of adoptively transferred tumor-reactive T cells associated with tumor regression.

Huang J, Khong HT, Dudley ME, El-Gamil M, Li YF, Rosenberg SA, Robbins PF.

J Immunother. 2005 May-Jun;28(3):258-67.

24.

Cutting edge: persistence of transferred lymphocyte clonotypes correlates with cancer regression in patients receiving cell transfer therapy.

Robbins PF, Dudley ME, Wunderlich J, El-Gamil M, Li YF, Zhou J, Huang J, Powell DJ Jr, Rosenberg SA.

J Immunol. 2004 Dec 15;173(12):7125-30.

25.
26.

Identification of a colorectal tumor-associated antigen (COA-1) recognized by CD4(+) T lymphocytes.

Maccalli C, Li YF, El-Gamil M, Rosenberg SA, Robbins PF.

Cancer Res. 2003 Oct 15;63(20):6735-43.

27.
28.

Generation of NY-ESO-1-specific CD4+ and CD8+ T cells by a single peptide with dual MHC class I and class II specificities: a new strategy for vaccine design.

Zeng G, Li Y, El-Gamil M, Sidney J, Sette A, Wang RF, Rosenberg SA, Robbins PF.

Cancer Res. 2002 Jul 1;62(13):3630-5.

30.

Melanoma-Reactive CD8+ T cells recognize a novel tumor antigen expressed in a wide variety of tumor types.

Harada M, Li YF, El-Gamil M, Ohnmacht GA, Rosenberg SA, Robbins PF.

J Immunother. 2001 Jul-Aug;24(4):323-33.

PMID:
11565834
31.

Use of an in vitro immunoselected tumor line to identify shared melanoma antigens recognized by HLA-A*0201-restricted T cells.

Harada M, Li YF, El-Gamil M, Rosenberg SA, Robbins PF.

Cancer Res. 2001 Feb 1;61(3):1089-94.

32.

Nuclear beta-catenin displays GSK-3beta- and APC-independent proteasome sensitivity in melanoma cells.

Bonvini P, Hwang SG, El-Gamil M, Robbins P, Kim JS, Trepel J, Neckers L.

Biochim Biophys Acta. 2000 Feb 28;1495(3):308-18.

33.

Melanoma cell lines contain a proteasome-sensitive, nuclear cytoskeleton-associated pool of beta-catenin.

Bonvini P, Hwang SG, el-Gamil M, Robbins P, Neckers L, Trepel J.

Ann N Y Acad Sci. 1999;886:208-11. Review. No abstract available.

PMID:
10667221
34.

The intronic region of an incompletely spliced gp100 gene transcript encodes an epitope recognized by melanoma-reactive tumor-infiltrating lymphocytes.

Robbins PF, El-Gamil M, Li YF, Fitzgerald EB, Kawakami Y, Rosenberg SA.

J Immunol. 1997 Jul 1;159(1):303-8.

PMID:
9200467
35.

Stabilization of beta-catenin by genetic defects in melanoma cell lines.

Rubinfeld B, Robbins P, El-Gamil M, Albert I, Porfiri E, Polakis P.

Science. 1997 Mar 21;275(5307):1790-2.

36.

Identification of tyrosinase-related protein 2 as a tumor rejection antigen for the B16 melanoma.

Bloom MB, Perry-Lalley D, Robbins PF, Li Y, el-Gamil M, Rosenberg SA, Yang JC.

J Exp Med. 1997 Feb 3;185(3):453-9.

37.

A mutated beta-catenin gene encodes a melanoma-specific antigen recognized by tumor infiltrating lymphocytes.

Robbins PF, El-Gamil M, Li YF, Kawakami Y, Loftus D, Appella E, Rosenberg SA.

J Exp Med. 1996 Mar 1;183(3):1185-92.

38.

Melanoma tumor-infiltrating lymphocytes derived from four distinct anatomic sites obtained from a single patient: comparison of functional reactivity and melanoma antigen recognition.

Yannelli JR, McConnell S, Parker L, Nishimura M, Robbins P, Yang J, el Gamil M, Kawakami Y.

J Immunother Emphasis Tumor Immunol. 1995 Nov;18(4):263-71.

PMID:
8680654
39.

Identification of a tyrosinase epitope recognized by HLA-A24-restricted, tumor-infiltrating lymphocytes.

Kang X, Kawakami Y, el-Gamil M, Wang R, Sakaguchi K, Yannelli JR, Appella E, Rosenberg SA, Robbins PF.

J Immunol. 1995 Aug 1;155(3):1343-8.

PMID:
7543520
40.

Cloning of a new gene encoding an antigen recognized by melanoma-specific HLA-A24-restricted tumor-infiltrating lymphocytes.

Robbins PF, el-Gamil M, Li YF, Topalian SL, Rivoltini L, Sakaguchi K, Appella E, Kawakami Y, Rosenberg SA.

J Immunol. 1995 Jun 1;154(11):5944-50.

PMID:
7751637
41.
42.

Recognition of tyrosinase by tumor-infiltrating lymphocytes from a patient responding to immunotherapy.

Robbins PF, el-Gamil M, Kawakami Y, Stevens E, Yannelli JR, Rosenberg SA.

Cancer Res. 1994 Jun 15;54(12):3124-6. Erratum in: Cancer Res 1994 Jul 15;54(14):3952.

43.

Targeted cytokine production.

Segal DM, Qian JH, Titus JA, Moreno MB, George AJ, Jost CR, Kurucz I, el-Gamil M, Wunderlich JR.

Int J Cancer Suppl. 1992;7:36-8. Review.

PMID:
1428400
44.

Expression of swine class II genes using recombinant retroviral vectors.

LeGuern C, Shafer GE, Alexander RC, Germana S, Gustafsson K, el-Gamil M, Sachs DH.

Transplant Proc. 1991 Feb;23(1 Pt 1):427-8. No abstract available.

PMID:
1846714
45.

Class II genes of miniature swine. II. Molecular identification and characterization of B (beta) genes from the SLAc haplotype.

Pratt K, Sachs DH, Germana S, el-Gamil M, Hirsch F, Gustafsson K, LeGuern C.

Immunogenetics. 1990;31(1):1-6.

PMID:
2298461
46.

Class II genes of miniature swine. I. Class II gene characterization by RFLP and by isolation from a genomic library.

Sachs DH, Germana S, el-Gamil M, Gustafsson K, Hirsch F, Pratt K.

Immunogenetics. 1988;28(1):22-9.

PMID:
2897949
47.

Inhibition of the catalytic properties of Staphylococcus aureus nuclease by monoclonal antibodies.

Devaux CA, Covell DG, Barbet J, el Gamil M, Sachs DH.

Mol Cell Biochem. 1987 Apr;74(2):117-28.

PMID:
2439893
48.
49.

Complementation between I region genes is revealed by a hybridoma anti-Ia antibody.

Sachs DH, el-Gamil M, Arn JS, Ozato K.

Transplantation. 1981 Apr;31(4):308-10. No abstract available.

PMID:
6939161
50.

Evidence for the absence of I-E/C antigen expression on the cell surface in mice of the H-2b or H-2s haplotypes.

Ozato K, Lunney JK, El-Gamil M, Sachs DH.

J Immunol. 1980 Aug;125(2):940-5.

PMID:
7391587

Supplemental Content

Loading ...
Support Center